<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Palliative jaw-sparing treatment of a non-resectable canine oral fibrosarcoma using combination of electrochemotherapy with bleomycin and IL-12 gene electrotransfer</dc:title><dc:creator>Pavlin,	Darja	(Avtor)
	</dc:creator><dc:creator>Nemec,	Ana	(Avtor)
	</dc:creator><dc:creator>Lampreht Tratar,	Urša	(Avtor)
	</dc:creator><dc:creator>Čemažar,	Maja	(Avtor)
	</dc:creator><dc:creator>Brožič,	Andreja	(Avtor)
	</dc:creator><dc:creator>Serša,	Gregor	(Avtor)
	</dc:creator><dc:creator>Tozon,	Nataša	(Avtor)
	</dc:creator><dc:description>Abstract: A 15-year-old male castrated English setter was presented for evaluation of a rapidly growing oral mass. Patient’s history was otherwise unremarkable, except of moderate proteinuria of 5 years duration. Clinical examination findings were within normal limits, except of an ulcerated located at the left mandibular canine tooth, which was histologically confirmed as a high grade infiltrative fibrosarcoma with high mitotic index (61/10 HPF) and multifocal necrotic areas. The client declined full staging, so only hematological and biochemistry examinations of blood were performed, which were without any clinically significant alterations. Furthermore a fine needle aspiration biopsy of regional lymph nodes was performed, which revealed reactive lymphadenopathy without signs of metastases. After declining other more invasive therapeutic procedures, the clients elected treatment with combination of electrochemotherapy and IL-12 electrogene therapy. Four consecutive treatment sessions were performed, resulting not only in complete response of the primary tumor, but also in regression of untreated distant metastasis, which was diagnosed approximately one month after the initial examination.  Furthermore, the percentage of circulating CD8+ cells was increased after each therapy session, indicating possible systemic induction of immune response by IL-12 gene therapy. This case shows that this type of therapy can represent an alternative type of both local and systemic treatment in selected tumor cases, where clients seek a less invasive nonsurgical treatment.</dc:description><dc:date>2021</dc:date><dc:date>2021-10-11 13:03:28</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>132071</dc:identifier><dc:identifier>UDK: 602.621:616.31-006:615:636.7</dc:identifier><dc:identifier>ISSN pri članku: 1580-4003</dc:identifier><dc:identifier>DOI: 10.26873/SVR-1148-2020</dc:identifier><dc:identifier>COBISS_ID: 58436867</dc:identifier><dc:language>sl</dc:language></metadata>
